Jun 05, 2024
Immutep successfully completes institutional placement and institutional component of entitlement offer
Jun 03, 2024
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial
May 15, 2024
Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024
May 02, 2024
Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma
Apr 28, 2024
Immutep Quarterly Activities Report Q3 FY24
Apr 23, 2024
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
Apr 18, 2024
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761
Apr 17, 2024
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Mar 05, 2024
Immutep Announces First Clinical Data from 90mg Dosing of Efti
Jan 30, 2024
Immutep Quarterly Activities Report Q2 FY24
Jan 04, 2024
First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer
Dec 20, 2023
Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
